Singapore markets closed

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.5750-0.0650 (-1.40%)
As of 10:55AM EST. Market open.

MannKind Corporation

30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
United States
818 661 5000

Full-time employees240

Key executives

NameTitlePayExercisedYear born
Dr. Michael E. CastagnaCEO & Director983kN/A1977
Mr. Steven B. BinderChief Financial Officer674.71kN/A1963
Mr. Joseph KocinskyChief Technology Officer642.92kN/A1964
Dr. David B. ThomsonExec. VP, Gen. Counsel & Sec.728.74kN/A1967
Dr. Stuart A. TrossChief People & Workplace Officer638.38kN/A1967
Ms. Rosabel Realica AlinayaVP of Investor Relations & TreasuryN/AN/A1961
Mr. John F. BedardSr. VP of Worldwide Regulatory AffairsN/AN/A1950
Mr. James Patrick McCauley Jr., J.D., M.B.A.Chief Commercial OfficerN/AN/A1966
Mr. Alejandro Galindo M.B.A., M.S.Chief Commercial OfficerN/AN/A1972
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-ß inhibitor for the treatment of pulmonary fibrosis. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Corporate governance

MannKind Corporation’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.